

MICHAEL S. LEONG, M.D.

Date of Birth: December 28, 1967
Place of Birth: Vancouver, Canada
Place of Citizenship: U.S.A.

Clinic Address:

Stanford Pain Medicine Center
450 Broadway Street
Pavilion A, Suite A18
Redwood City, CA 94063
Tele: (650) 723-6238
Fax: (650) 721-3414
Cell: (650) 799-3400
E-mail: msleong@stanford.edu

Administrative Contact:

Alyssa Martinez
Tele: (650) 721-7286
Fax: (650) 721-3471
E-mail: amart10@stanford.edu

Professional Experience:

Clinic Chief, Stanford Pain Management Center

Mar. 2010 – Present

- Oversee and manage the Pain Center
- Assist Division Chief with strategic planning and budgeting for Pain Center
- Create, educate, and implement new clinic policies and procedures
- Conduct community outreach to lay public via community lectures, educational materials, media contacts
- Develop and manage marketing and public relations
 - Community and Stanford physicians
 - Establish regular communications with referring physicians and clinics via newsletters, emails, and other media
 - Hold regular vis a vis meetings with referring and potential referring physicians
 - Payors
 - Develop relations with workers compensation companies and other insurance groups
 - Give targeted lectures, meetings, flyers
- Enhance quality improvement and develop outcomes metrics
- Review utilization of clinic resources
- Oversee credentialing of Stanford pain medicine physicians
- Coordinate interface between clinical research and medical staff

Pain Medicine Specialist in Los Gatos and Salinas, CA

Jan. 2009 – Feb. 2010

- Ran comprehensive pain medicine practice
- Served as clinical research investigator / pharmaceutical industry consultant for novel analgesics

Medical Director, XenoPort, Inc.

Aug. 2007 – Dec. 2008

- Supervised Phase 2a clinical trial in Spasticity with XP19986 (Baclofen prodrug)
 - Developed protocol and investigator brochure, served on advisory boards and developed KOL, oversaw initiation and site selection, served as medical monitor for trial
- Prepared for pre-IND meeting for XP19986 (Baclofen prodrug) for Acute Neck and Back Spasms
 - Developed protocol, clinical plan, and KOL, oversaw initiation and site selection, served as medical monitor for trial

- Prepared for Phase 1 clinical trial with XP20925 (Propofol prodrug) for Migraines
 - Developed protocol and investigator brochure, oversaw initiation and site selection
- Developed key opinion leader relationships in novel therapeutic areas for the company

Director, Clinical Research, Anesiva, Inc.

May 2006 – Jul. 2007

- Attended and prepared for the pre-NDA meeting for *Zingo*
- Completed Phase 1 clinical trial of 1207
 - Developed protocol and investigator brochure, oversaw initiation and site selection in Australia, collected and analyzed data, completed trial within 6 months (well sooner than anticipated timelines)
- Prepared clinical review for submission of eCTD for *Zingo* with approval in 2007
- Completed Phase 3 adult clinical trial with *Zingo*
 - Developed protocol and investigator brochure, oversaw initiation and site selection, served as medical monitor for trial
- Completed Phase 2 clinical trials in postoperative clinical trials with TKA, shoulder arthroscopy with 4975
 - Developed protocol and investigator brochure, served on advisory boards and developed KOL, oversaw initiation and site selection
- Prepared publication and manuscript for *Zingo* launch
- Presented poster and abstract at pain management conferences
- Performed clinical analysis and due diligence for business development in-licensing opportunities
- Developed key opinion leader relationships in novel therapeutic areas for the company

Medical Director, Medical Affairs, Solstice Neurosciences, Inc.

Mar. 2005 – May 2006

- Supervised the implementation and operations of sponsored and investigator-initiated studies in a variety of neuroscience areas with Botulinum Toxin Type B - *Myobloc*
- Served as member of Protocol Review Committee for sponsored IRB trials, and member of Copy Clearance Committee to represent medical affairs team for regulatory and compliance issues
- Reviewed pharmacovigilance and safety reports and provided input
- Managed medical information services and publications groups
- Collaborated with marketing to establish medical education and communications programs, reviewed promotional and sales force training materials and provided scientific training for sales force
- Provided scientific input to clinical development plan
- Developed opinion leader relationships in novel therapeutic areas for the company

Attending Pain Management Specialist, Bay Area Pain Center, Los Gatos, CA

Apr. 2002 – Feb. 2005

- Provided pain management services, with specialty in treatment of neuropathic pain and management of intrathecal pumps
- Served as clinical trial investigator for multi-center pharmaceutical company sponsored research for novel oral, topical, and intrathecal analgesics (Gabapentin prodrug - *Solzira*, topical Cannabinoid - *Anandamide*, N-type Calcium Channel blocker - *Prialt*)
- Served as staff physician at Los Gatos Community Hospital, Good Samaritan Hospital, El Camino Hospital

Academic Appointments

May 2012 – Present

Clinical Associate Professor of Anesthesia and Pain Medicine
Stanford University Medical Center

Mar 2009 – Apr 2012

Clinical Assistant Professor of Anesthesia and Pain Medicine

Stanford University Medical Center

May 2002 – Feb 2009

Adjunct Assistant Professor of Anesthesia
Stanford University Medical Center

Jul 1998 – Mar 2002

Clinical Instructor to Assistant Professor of Anesthesia
Stanford University Medical Center

Education and Training:

Jul 1997 – Jun 1998

Anesthesia Pain Management Fellow
Stanford University School of Medicine
Stanford, California

Oct 1995 – Jun 1997

Anesthesiology Residency
Stanford University School of Medicine
Stanford, California

Jul 1994 – Sept 1995

Anesthesiology Residency
University of California, Davis Medical Center
Sacramento, California

Jul 1993 – Jun 1994

Internal Medicine Internship
George Washington University Medical Center

Aug 1989 – May 1993

Doctor of Medicine
Georgetown University Medical School

Aug 1985 – May 1989

Bachelor of Science degree in Biology
Santa Clara University
Magna Cum Laude

Medical Licensure:

California License # A53960

Board Certification:

Diplomat of American Board of Anesthesiologists (ABA) 1999
Subspecialty Certification in Pain Management (ABA) 2000
Recertification for Pain Management (ABA) through 2020

Professional Associations:

American Society of Regional Anesthesia and Pain Medicine
International Association for the Study of Pain (IASP)
American Academy of Pain Medicine
American Pain Society
American Society of Anesthesiology
California Society of Anesthesiologists
American College of Physician Executives

Research as Principle Investigator:

1. **Leong M** (P.I), Abaci P, Massey J. *A randomized, open-label study of the tolerability of three local anesthetic formulations in conjunction with NGX-4010 for the treatment of neuropathic pain.* Protocol C111 Sponsored by Neurogesx, January 27, 2004.
2. **Leong M** (P.I), Abaci P, Massey J. *An open-label, long-term, multi-center, intrathecal Ziconotide (Prialt) effectiveness and safety trial (ZEST) in patients with chronic severe pain.* Protocol ELN92045-501 Sponsored by Elan, January 17, 2004.
3. **Leong M** (P.I), Abaci P, Massey J. *An open-label, long-term, multicenter study of Ziconotide administered intrathecally.* Protocol ELN92045-352 Sponsored by Elan, April 28, 2003.
4. **Leong M** (P.I), Abaci P, Massey J. *Study of Gabapentin Pharmacokinetic Variability.* Protocol XP001 Sponsored by Xenoport, March 20, 2003.
5. **Leong M** (P.I), Abaci P, Massey J. *A double-blind, vehicle-controlled, single dose study to Assess the safety, tolerability, and efficacy of topical KDS-2000 (anandamide) in patients with postherpetic neuralgia.* Protocol 2000-201 Sponsored by Kadmus, December 4, 2002.
6. **Leong M** (P.I), Abaci P, Massey J. *A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain.* Protocol ELN92045-301 Sponsored by Elan, March 27, 2002.

Peer-Reviewed Publications:

1. Gewandter JS, Dworkin RH, Turk DC, McDermott MP, Baron R, Gastonguay MR, Gilron I, Katz NP, Mehta C, Raja SN, Senn S, Taylor C, Cowan P, Desjardins P, Dimitrova R, Dionne R, Farrar JT, Hewitt DJ, Iyengar S, Jay GW, Kalso E, Kerns RD, Leff R, **Leong M**, Petersen KL, Ravina BM, Rauschkolb C, Rice AS, Rowbotham MC, Sampaio C, Sindrup SH, Stauffer JW, Steigerwald I, Stewart J, Tobias J, Treede RD, Wallace M, White RE. *Research designs for proof-of-concept chronic pain clinical trials: IMMPACT recommendations.* Pain, 2014, 155:1683-1695.
2. Deer TR, Krames E, Mekhail N, Pope J, **Leong M**, Stanton-Hicks M, Golovac S, Kapural L, Alo K, Anderson J, Foreman RD, Caraway D, Narouze S, Linderoth B, Buvanendran A, Feler C, Poree L, Lynch P, McJunkin T, Swing T, Staats P, Liem L, Williams K. *The appropriate use of neurostimulation: new and evolving neurostimulation therapies and applicable treatment for chronic pain and selected disease states.* Neuromodulation, 2014, 17:599-615.
3. Deer TR, Mekhail N, Provenzano D, Pope J, Krames E, Thomson S, Raso L, Burton A, DeAndres J, Buchser E, Buvanendran A, Liem L, Kumar K, Rizvi S, Feler C, Abejon D, Anderson J, Eldabe S, Kim P, **Leong M**, Hayek S, McDowell G 2nd, Poree L, Brooks ES, McJunkin T, Lynch P, Kapural L, Foreman RD, Caraway D, Alo K, Narouze S, Levy RM, North R. *The appropriate use of neurostimulation: avoidance and treatment of complications of neurostimulation therapies for the treatment of chronic pain.* Neuromodulation, 2014, 17:571-598.
4. Deer TR, Mekhail N, Provenzano D, Pope J, Krames E, **Leong M**, Levy RM, Abejon D, Buchser E, Burton A, Buvanendran A, Candido K, Caraway D, Cousins M, DeJongste M, Diwan S, Eldabe S, Gatzinsky K, Foreman RD, Hayek S, Kim P, Kiefe T, Kloth D, Kumar K, Rizvi S, Lad SP, Liem L, Linderoth B, Mackey S, McDowell G, McRoberts P, Poree L, Prager J, Raso L,

- Rauck R, Russo M, Simpson B, Slavin K, Staats P, Stanton-Hicks M, Verrills P, Wellington J, Williams K, North R. *The appropriate use of neurostimulation of the spinal cord and peripheral nervous system for the treatment of chronic pain and ischemic diseases: the neuromodulation appropriateness consensus committee.* Neuromodulation, 2014, 17:515-550.
5. Huang B, Yao M, Feng Z, Guo J, Zereshki A, **Leong M**, Qian X. *CT-Guided Percutaneous Infrazygomatic Radiofrequency Neurolysis Through Foramen Rotundum to Treat V2 Trigeminal Neuralgia.* Pain Medicine, 2014, 8:1418-1428.
 6. Heifets BD, Smith SM, **Leong MS**. *Acute Cardiovascular Toxicity of Low-Dose Intrathecal Ziconotide.* Pain Medicine, 2013, 11:1807-1809.
 7. Deer TR, Prager J, Levy R, Rathmell J, Buchser E, Burton A, Caraway D, Cousins M, De Andrés J, Diwan S, Erdek M, Grigsby E, Huntoon M, Jacobs MS, Kim P, Kumar K, **Leong M**, Liem L, McDowell GC, Panchal S, Rauck R, Saulino M, Sitzman BT, Staats P, Stanton-Hicks M, Stearns L, Wallace M, Willis KD, Witt W, Yaksh T, Mekhail N. *Polyanalgesic Consensus Conference 2012: Consensus on Diagnosis, Detection, and Treatment of Catheter-tip Granulomas (Inflammatory Masses).* Neuromodulation, 2012, 5:483-496.
 8. Deer TR, Prager J, Levy R, Rathmell J, Buchser E, Burton A, Caraway D, Cousins M, De Andrés J, Diwan S, Erdek M, Grigsby E, Huntoon M, Jacobs MS, Kim P, Kumar K, **Leong M**, Liem L, McDowell GC, Panchal S, Rauck R, Saulino M, Sitzman BT, Staats P, Stanton-Hicks M, Stearns L, Wallace M, Willis KD, Witt W, Yaksh T, Mekhail N. *Polyanalgesic Consensus Conference 2012: Recommendations to Reduce Morbidity and Mortality in Intrathecal Drug Delivery in the Treatment of Chronic Pain.* Neuromodulation, 2012, 5:467-482.
 9. Deer TR, Prager J, Levy R, Rathmell J, Buchser E, Burton A, Caraway D, Cousins M, De Andrés J, Diwan S, Erdek M, Grigsby E, Huntoon M, Jacobs MS, Kim P, Kumar K, **Leong M**, Liem L, McDowell GC, Panchal S, Rauck R, Saulino M, Sitzman BT, Staats P, Stanton-Hicks M, Stearns L, Wallace M, Willis KD, Witt W, Yaksh T, Mekhail N. *Polyanalgesic Consensus Conference 2012: Recommendations for the Management of Pain by Intrathecal (Intraspinal) Drug Delivery: Report of an Interdisciplinary Expert Panel.* Neuromodulation, 2012, 5:436-466.
 10. Deer TR, Prager J, Levy R, Rathmell J, Buchser E, Burton A, Caraway D, Cousins M, De Andrés J, Diwan S, Erdek M, Grigsby E, Huntoon M, Jacobs MS, Kim P, Kumar K, **Leong M**, Liem L, McDowell GC, Panchal S, Rauck R, Saulino M, Sitzman BT, Staats P, Stanton-Hicks M, Stearns L, Wallace M, Willis KD, Witt W, Yaksh T, Mekhail N. *Polyanalgesic Consensus Conference 2012: Recommendations on Trialing for Intrathecal (Intraspinal) Drug Delivery: Report of an Interdisciplinary Expert Panel.* Neuromodulation, 2012, 5:420-435.
 11. Kapural L, Lokey K, **Leong MS**, Fiekowsky S, Stanton-Hicks M, Sapienza-Crawford AJ, Webster LR. *Intrathecal Ziconotide for Complex Regional Pain Syndrome: Seven Case Reports.* Pain Practice, 2009, 4:296-303.
 12. Wallace M, Kosek P, Staats P, Fisher R, Schultz D, **Leong M**. *Phase II, Open-Label, Multicenter Study of Combined Intrathecal Morphine and Ziconotide: Addition of Ziconotide in Patients Receiving Intrathecal Morphine for Severe Chronic Pain.* Pain Medicine, 2008, 9:271-281.
 13. Zempsky W, Robbins B, Richards P, **Leong M**, Schechter N. *A Novel Needle-Free Powder Lidocaine Delivery System for Rapid Local Analgesia.* J Pediatr, 2008, 152:405-411.

14. Carruthers A, Carruthers J, Flynn T, **Leong M**. *Dose-finding, Safety, and Tolerability Study of Botulinum Toxin Type B for the Treatment of Hyperfunctional Glabellar Lines*. Dermatol Surg, 2007, 33:S60-S68.
15. Rauck RL, Wallace MS, **Leong MS**, Minehart M, Webster LR, Charapata SG, Abraham JE, Buffington DE, Ellis D, Kartzinel R. *A Randomized, Double-blind, Placebo-controlled Study of Intrathecal Ziconotide in Adults with Severe Chronic Pain*. J Pain Symptom Manage, 2006, 5:393-406.
16. Fisher R, Hassenbusch S, Krames E, **Leong M**, Minehart M, Prager J, Staats P, Webster L, Willis KD. *A Consensus Statement Regarding the Present Suggested Titration for Prialt (Ziconotide)*. Neuromodulation, 2005, 3:153-154.
17. **Leong M**, Isolani F, Gaeta R. *Mexilitine and Persistent Ophthalmic Changes*. Pain Medicine, September 2001, 2:228-9.
18. **Leong M**, Carpentier B. *Intraspinal pump battery assessment: Cold, Old, or Dead!* Neuromodulation, July 2001, 4:117-120.
19. **Leong M**. *Book Review of 'Management of Acute and Chronic Pain' By Rawal N*. Regional Anesthesia and Pain Medicine, July 2001, 26:380.
20. **Leong M**, Heit G. *Intraventricular administration of morphine and clonidine*. Anesthesiology, June 2001, 94:1141-3.
21. **Leong M**, Mackey S. *Delayed subdural anesthesia after stellate ganglion block*. Anesthesiology, February 2001, 94:358-9.
22. **Leong M**, Solvason B. *'Flashback' elicited by intravenous lidocaine in a patient with a Chronic Pain disorder and major depression*. Pain Medicine, December 2000, 1:358-61.
23. Patterson A, **Leong M**, Brodsky J, Mark J. *Airway obstruction caused by an oleothorax*. Journal of Cardiothoracic and Vasc Anes, April 1998, 12:189-91.

Textbooks and Chapters:

1. Deer TR, **Leong MS**, Buvanendran A, Gordin V. Comprehensive Treatment of Chronic Pain by Medical, Interventional, and Integrative Approaches: The American Academy of Pain Medicine Textbook on Patient Management. Springer, 2013.
2. Krane E, **Leong M**, Golianu B, Leong Y. *Treatment of pediatric pain with non-conventional analgesics in Pain in Infants, Children, and Adolescents*, Berde, Schechter, and Yaster Ed., 2002 (book chapter).

Submitted Manuscripts:

1. Grigsby EJ, Bruel BM, **Leong M**. *Use of Trialing in Intrathecal Therapy for Chronic Pain*. Submitted to Pain Physician: April 7, 2014.

Poster Presentations:

1. **Leong M.** *Current CRPS Treatments and Efficacy.* Complex Regional Pain Syndrome/RSD Litigation Group; Los Angeles, CA; July 22, 2016.
2. **Leong M.** *Resiniferatoxin: A potent TRPV1 agonist.* Neuromodulation the Science; San Francisco, CA; May 25-29, 2016.
3. **Leong M,** Dupoirion D. *Evolving Technologies.* Second Annual Cancer Pain Research Consortium Conference: Multidisciplinary Cancer Pain Relief: From Evidence to Practice; Scottsdale, AZ; April 14-16, 2016.
4. Bunch J, **Leong M.** *Slowly Titrated Intrathecal Ziconotide Completely Ameliorated Chronic Post Herpetic Neuralgia in a Patient Whose Pain Was Refractory: An Optimized Medication Regimen, Radiofrequency Ablations, Spinal Cord Stimulation, and Intrathecal Opioid Therapy.* Pain Medicine. 2016, 17 (2): 386.
5. Kao M, Mackey I, Valenzuela E, Prasad R, Sugarman K, **Leong M,** Myers S. *Network of Coordinated Care: Collaborative Relationship of Pain Medicine with Primary Care for Complex Patients with Pain: A Large-Scale Network Study Using a Learning Health System Platform.* Pain Medicine. 2016, 17 (2): 414.
6. Kao M, **Leong M,** Sugarman K, Myers S, Valenzuela E, Mackey S. *Identifying High Call Center Utilizers in a Pain Management Center: Algorithmic Detection for Early Intervention Using a Learning Health System Platform.* Pain Medicine. 2016, 17 (2): 415.
7. Kao M, Mackey S, **Leong M,** Darnall B, Valenzuela E. *System to Enhance Patient Experience (STEPx): Machine-Mediated Classification of Patient Experience Feedback Using Natural Language Processing.* Pain Medicine. 2016, 17 (2): 416.
8. Caraway D, **Leong D.** *Pharmacodynamic Risks of Intrathecal Therapy as Compared with Oral.* Pearls and Pitfalls of Intrathecal Drug Delivery Systems: The North American Neuromodulation Society Meeting. Las Vegas, NV. December 9-11, 2015.
9. Deer TR, Caraway D, Grigsby EJ, **Leong MS,** Rauck RL, Saulino MF, Kim PS, Wallace M, McDowell G, Huang IZ, Alvarez-Horine S, Vanhove T. *The PRIZM (Patient Registry of Intrathecal Ziconotide Management) study for patients with severe chronic pain: results from an interim analysis.* American Society of Regional Anesthesia and Pain Medicine 13th Annual Meeting; San Francisco, CA; November 13-16, 2014.
10. **Leong M,** Davis E. *Cancer pain treated with intrathecal bolus ziconotide treatments.* International Association for the Study of Pain 15th World Congress on Pain; Buenos Aires, Argentina; October 6-11, 2014.
11. **Leong M,** Davis E. *Evaluation of stepwise rapid titration trial of ziconotide in the ability to predict success of future therapy.* International Association for the Study of Pain 15th World Congress on Pain; Buenos Aires, Argentina; October 6-11, 2014.
12. Rauck RL, Caraway D, Grigsby EJ, **Leong MS,** Saulino MF, Deer TR, Kim PS, Wallace M, McDowell G, Hokett S, Alvarez-Horine S, Vanhove G. *The PRIZM (Patient Registry of Intrathecal Ziconotide Management) study for patients with severe chronic pain.* American Academy of Pain Medicine 30th Annual Meeting; Phoenix, AZ; March 6-9, 2014.

13. **Leong M**, Davis E. *Progressive cancer pain from osteosarcoma treated combination ziconotide and hydromorphone*. 17th Annual Meeting of the North American Neuromodulation Society; Las Vegas, NV; December 5-8, 2013.
14. Kapural L, Lokey K, **Leong M**, Fiekowsky S, Stanton-Hicks M, Sapienza-Crawford A. *Intrathecal Ziconotide for Complex Regional Pain Syndrome: Seven Case Reports*. North American Neuromodulation Society 11th Annual Meeting; Acapulco, Mexico; December 7-12, 2007.
15. Carpentier B, **Leong M**. *Botulinum toxin type B: treatment degenerative osteoarthritic pain*. American Society of Regional Anesthesia Pain Annual Meeting; San Francisco, CA; November 16-19, 2006.
16. Zempsky W, Bean-Lijewski J, Kauffman R, Koh J, Malviya S, Rose J, **Leong M**. *Local analgesia within 1 to 3 minutes for pediatric venipuncture and peripheral venous cannulation procedures using the Needle-Free system 3268*. American Society of Regional Anesthesia Pain Annual Meeting; San Francisco, CA; November 16-19, 2006.
17. Fiekowsky S, **Leong M**. *Reversal of painful peripheral neuropathy with Prialt (Intrathecal Ziconotide) treatment*. North American Neuromodulation Society 10th Annual Meeting; Las Vegas, NV; December 7-9, 2006.
18. Carroll I, Baumgartl W, **Leong M**. *Botulinum toxin type B: treatment for multiple neuropathic pain conditions: scar neuromas, stump neuroma, postherpetic neuralgia*. 8th International Conference on the Mechanisms and Treatment of Neuropathic Pain; San Francisco, CA; November 3-5, 2005.
19. Diamond E, Miller T, **Leong M**. *4975 Reduces Pain of Intermetatarsal Neuroma: Preliminary results from a randomized, double-blind, placebo-controlled, Phase 2, multicenter, clinical trial*. 9th International Conference on the Mechanisms and Treatment of Neuropathic Pain; Bermuda; November 2-5, 2006.
20. **Leong M**, Royal M. *The MIND Registry: An Observational Database of Patients Treated with Botulinum Toxin Type B (Myobloc)*. American Neurological Association Annual Meeting; San Diego, CA; September 26-28, 2005.
21. Royal M, **Leong M**. *A review of pediatric adverse events associated with botulinum toxin type B*. American Neurological Association Annual Meeting; San Diego, CA; September 26-28, 2005.
22. Cleveland P, **Leong M**, Royal, M. *A Review of the Adult Adverse Events Associated with Botulinum Toxin Type B (Myobloc)*. Neurotoxicity Society's International Conference 2005 Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins; Denver, CO; June 23-25, 2005.
23. Heavner, J, **Leong M**, Royal M. *The MIND Registry: an observational database of patients treated with botulinum toxin type B (Myobloc) – Pain subset of the database*. Neurotoxicity Society's International Conference 2005 Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins; Denver, CO; June 23-25, 2005.
24. Sunter W, **Leong M**, Royal M. *The cervical dystonia subset of the MIND Registry database*. Neurotoxicity Society's International Conference 2005 Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins; Denver, CO; June 23-25, 2005.

25. **Leong M**, Royal M. *A randomized double-blind study to compare the efficacy and safety of NeuroBloc (Myobloc; botulinum toxin type B) with Botox (botulinum toxin type A) in toxin naïve subjects with cervical dystonia.* Neurotoxicity Society's International Conference 2005 Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins; Denver, CO; June 23-25, 2005.
26. Royal M, **Leong M**. *A review of pediatric adverse events associated with botulinum toxin type B.* Neurotoxicity Society's International Conference 2005 Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins; Denver, CO; June 23-25, 2005.
27. Royal M and **Leong M**. *The MIND Registry: An Observational Database of Patients Treated with Botulinum Toxin Type B (Myobloc) – Pain Subset of the Database.* American Society of Regional Anesthesia Pain Annual Meeting; Toronto, Canada; April 23, 2005.
28. **Leong M**, Ouimette A, Fiekowsky S. *Intrathecal Ziconotide (Prialt) Relieves Idiopathic Peripheral Neuropathic Pain: A Case Report.* American Pain Society Annual Scientific Meeting; Vancouver, Canada; May 6-9, 2004.
29. **Leong M**, Webster L, Ellis D, Gaeta R. *Identification of an Effective and Well-tolerated Dose Range for Ziconotide, a novel non-opioid Intrathecal Analgesic for Chronic Pain.* American Society of Clinical Oncology Annual Meeting; San Francisco, CA; May 12-15, 2001.
30. Webster L, Gaeta R, **Leong M**, Ellis D. *Ziconotide Efficacy in Patients with Chronic Intractable Pain of Malignant Origin: Efficacy as a Function of Patient Characteristics.* American Society of Clinical Oncology Annual Meeting; San Francisco, CA; May 12-15, 2001.